Companies › Sellas Life Sciences Group
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Galinpepimut-S Wilms tumor protein vaccine antigen | WT1 | Phase 3 | Acute Myeloid Leukemia | Dec 2026 |
| SLS009 CDK9 inhibitor | CDK9 | Phase 1 | Hematologic Malignancies | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04229979 | Galinpepimut-S | Phase 3 | Acute Myeloid Leukemia | Oncology | Dec 2026 |
| NCT04588922 | SLS009 | Phase 1 | Hematologic Malignancies | Oncology | Dec 2026 |
Cash of $138m on 2026-06-30; operating cash outflow about $33m a year; runway about 50 months at that burn, to Aug 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Erasca Hutchmed Nuvation Bio GC Cell Corvus Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.